Bayer, Pfizer and Ipsen-backed cancer therapeutics developer Pyxis Oncology priced its shares at the top of its range.
Author: Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Lightship ignites $40m round
McKesson Ventures has returned to back a $40m round for Lightship, having co-led a $20m series B last year.
Investors present $50m to CRM&Bonus
SoftBank’s Latin America Fund has thrown its weight behind CRM&Bonus as the customer loyalty platform accelerates its international expansion.
Exscientia establishes Nasdaq listing
SoftBank invested $125m through a $160m private placement as portfolio company and cancer drug developer Exscientia went public in an offering sized at nearly $305m.
Oxford Nanopore fetches $478m in IPO
Tencent, Nikon, Amgen and Illumina all scored exits as the DNA sequencing provider’s shares popped in the wake of its flotation.
Micreos makes space for new funding
Altria-backed Micreos is working on a clinical platform that will facilitate the targeted killing of unwanted bacteria, and has just secured $37.5m.
Kytopen constructs $30m series A
Alexandria Venture Investments participated in a $30m round for the gene therapy technology developer, which will use the capital to expand its partnerships.
Lilac Solutions blooms with $150m
Mercuria Energy Trading contributed to a round which will support the international growth of the lithium-extraction technology developer.
Omnidian orchestrates $33m series B
Liberty Mutual, Copec, National Grid, Evergy, Centrica and Avista all contributed to a round taking the solar maintenance technology developer’s total funding to at least $53m.
Oxford Nanopore sets IPO plans in motion
Oracle has committed $205m to an initial public offering for the DNA sequencing technology developer with a $410m target for its close.
Arctos accepts Novartis acquisition offer
Arctos Medical, which is developing gene therapies to treat sight loss, had raised $8.1m from investors including Novartis two years ago.
Inpria to process $514m acquisition
JSR is buying semiconductor manufacturing technology producer Inpria, giving an exit to fellow corporates SK Hynix, TSMC, Intel, Air Liquide, Applied Materials and Samsung.
Daily Deal Round Up: September 16, 2021
Immutable, Abra and Francis Medical have all raised more than $50m, while MAZ Systems has been acquired by Zype.
Vanqua Bio wins over series B investors
Eli Lilly was among the investors in neurodegenerative disease drug developer Vanqua Bio’s $85m series B round.